Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Clinical trial NCT05532696 · RECRUITING

Trial details

NCT number: NCT05532696
Sponsor: Anbogen Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Non Small Cell Lung Cancer HER2 Mutations

Start date: 2022-09-27
Primary completion: 2026-11-01
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.